Medical and Scientific: Breast cancer drug subsidy boost

29 Mar 2021 - Medical and Scientific

Breast cancer patients will have access to a lifesaving medicine on the Pharmaceutical Benefits Scheme from next month, slashing the cost of treatment from $50,000 to a few hundred dollars. The listing of a generic version of fulvestrant is a win for breast cancer campaigners who have been lobbying for years for the former patent holder, AstraZeneca, to submit an application to list the drug, called Faslodex, on the PBS. The government is also extending the PBS listing for several drugs that can fight lung cancer and severe asthma, and listing a drug for severe osteoporosis for the first time.

Sunday Age; 28/03/2021; Page 6; Sun Herald; 28/03/2021; Page 23